Corbus Pharmaceuticals (CRBP) Set to Release Quarterly Earnings on Wednesday

Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) is expected to release its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Corbus Pharmaceuticals to announce earnings of ($1.27) per share and revenue of $1.67 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 20, 2026 at 12:30 PM ET.

Corbus Pharmaceuticals Stock Performance

CRBP stock opened at $3.52 on Tuesday. The business has a 50 day moving average price of $6.28 and a 200 day moving average price of $8.45. Corbus Pharmaceuticals has a fifty-two week low of $2.81 and a fifty-two week high of $12.88.

Insider Activity

In other news, major shareholder Cormorant Asset Management, Lp sold 425,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $4.10, for a total transaction of $1,742,500.00. Following the transaction, the insider directly owned 1,919,971 shares in the company, valued at approximately $7,871,881.10. This trade represents a 18.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 3.50% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on CRBP shares. Mizuho set a $33.00 price objective on shares of Corbus Pharmaceuticals in a research report on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research report on Thursday, October 15th. Wall Street Zen lowered shares of Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Oppenheimer reduced their price target on shares of Corbus Pharmaceuticals from $52.00 to $48.00 and set an “outperform” rating for the company in a research report on Friday, August 7th. Finally, HC Wainwright restated a “buy” rating and issued a $35.00 price objective on shares of Corbus Pharmaceuticals in a research note on Monday, September 14th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Corbus Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $39.57.

View Our Latest Analysis on CRBP

About Corbus Pharmaceuticals

(Get Free Report)

Corbus Pharmaceuticals Holdings, Inc is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company’s research is centered on therapies designed to modulate immune-cell activity and target biological pathways involved in cancer and inflammatory disease.

Corbus’ oncology pipeline has included soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) being evaluated for its potential to treat T-cell lymphomas and other cancers.

Featured Stories

Earnings History for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.